Key Details
Price
$0.39Annual ROE
139.22%Beta
1.77Events Calendar
Next earnings date:
Feb 26, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Feb 26, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
FibroGen, Inc. (NASDAQ:FGEN ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A & IR Thane Wettig - CEO Juan Graham - CFO Conference Call Participants Andy Hsieh - William Blair Operator Good day and welcome to the FibroGen Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
FibroGen (FGEN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.52 per share a year ago.
FibroGen, Inc. (NASDAQ:FGEN ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David DeLucia - CFA Vice President, Corporate FP&A & Investor Relations Thane Wettig - Chief Executive Officer Deyaa Adib - Chief Medical Officer Juan Graham - Chief Financial Officer Chris Chung - Senior Vice President, China Operations Conference Call Participants Dalton Greenwood - William Blair Dina Ramadane - Bank of America Paul Choi - Goldman Sachs Operator Good day and welcome to the FibroGen Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
FibroGen (FGEN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.65 per share a year ago.
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen's immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron's anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression.
SAN FRANCISCO, May 23, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study conducted by the University of California San Francisco of FG-3246 (FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with a MMAE-containing payload, in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Stocks are at the mercy of many factors, and often, prices are just a poor earnings report or a negative headline away from a significant drop. There are times when nobody has any way of preparing.
FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript
The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
FAQ
- What is the primary business of FibroGen?
- What is the ticker symbol for FibroGen?
- Does FibroGen pay dividends?
- What sector is FibroGen in?
- What industry is FibroGen in?
- What country is FibroGen based in?
- When did FibroGen go public?
- Is FibroGen in the S&P 500?
- Is FibroGen in the NASDAQ 100?
- Is FibroGen in the Dow Jones?
- When was FibroGen's last earnings report?
- When does FibroGen report earnings?
- Should I buy FibroGen stock now?